Eight-month-old Bohdi became the first person to receive targeted medication for KCNT1 catastrophic epilepsy. The condition had caused up to 60 seizures a day.
Why it mattersThe breakthrough offers hope to 17 other Australians with this condition. It shows how targeted medicine can help ultra-rare diseases that previously had no treatment options.
AustraliaNSW's Innovative Therapies Pathway now serves as a model for rapid, personalised treatment of rare childhood diseases, potentially opening doors for other Australian families facing similar diagnoses.
Corroborated by7news.com.au
✓ Claims checked against the source. checked 2 h ago
Free. Sign in once, be genuinely informed in five minutes a day.
Tomorrow's edition, every morning.
Get the free app, read the whole feed
InSnip turns the day's news into short, source-backed snippets with a plain why it matters line. The signal, not the scroll.